The NIAID Division of AIDS (DAIDS) maintains resources for preclinical gap-filling support to develop promising HIV therapeutics and to enable filing an Investigational New Drug (IND) application with the Food and Drug Administration. The Resources Access for Preclinical Integrated Drug Development (RAPIDD) Program provides a standard way for investigators to request gap-filling services and is intended to reduce barriers in the drug development process
This announcement supports the National Institute of Allergy and Infectious Diseases (NIAID) mission to conduct and support basic and applied research to treat infectious diseases with a focus on:
(1) Development of Next-Generation HIV Therapies (drugs with improved safety and ease of use, e.g., sustained release antiretrovirals; novel HIV targets & inhibitors; novel immune-based therapies) and
(2) Addressing HIV-associated comorbidities, coinfections, and complications.